NASDAQ:ACHV Achieve Life Sciences Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Achieve Life Sciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.43 +0.15 (+1.62 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$8.80Now: $9.43▼$9.4450-Day Range$7.31MA: $9.04▼$11.7352-Week Range$4.51Now: $9.43▼$48.60Volume116,815 shsAverage Volume248,182 shsMarket Capitalization$33.83 millionP/E RatioN/ADividend YieldN/ABeta1.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes smoking cessation aids in the United States and internationally. The company offers Cytisine, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has a license agreement with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAchieve Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $47.75, Achieve Life Sciences has a forecasted upside of 406.4% from its current price of $9.43.Amount of Analyst CoverageAchieve Life Sciences has only been the subject of 3 research reports in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesAchieve Life Sciences has received 308 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAchieve Life Sciences has received 272 “underperform” votes. (Add your “underperform” vote.)Community SentimentAchieve Life Sciences has received 53.10% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Achieve Life Sciences and other stocks. Vote “Outperform” if you believe ACHV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ACHV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAchieve Life Sciences does not currently pay a dividend.Dividend GrowthAchieve Life Sciences does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Achieve Life Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.30% of the stock of Achieve Life Sciences is held by insiders. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Achieve Life Sciences are expected to grow in the coming year, from ($8.18) to ($6.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Achieve Life Sciences is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Achieve Life Sciences is -0.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAchieve Life Sciences has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.49 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Diagnostic substances Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:ACHV Previous Symbol CUSIP68230A10 CIK949858 Webachievelifesciences.com Phone604-210-2217Debt Debt-to-Equity Ratio0.01 Current Ratio6.99 Quick Ratio6.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.24 per share Price / Book0.77Profitability EPS (Most Recent Fiscal Year)($39.80) Net Income$-16,400,000.00 Net MarginsN/A Return on Equity-94.12% Return on Assets-79.84%Miscellaneous Employees13 Outstanding Shares3,587,000Market Cap$33.83 million Next Earnings Date11/4/2020 (Estimated) OptionableNot Optionable $9.43 +0.15 (+1.62 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ACHV News and Ratings via Email Sign-up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter. Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions How has Achieve Life Sciences' stock been impacted by COVID-19 (Coronavirus)? Achieve Life Sciences' stock was trading at $8.3240 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ACHV stock has increased by 13.3% and is now trading at $9.43. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Achieve Life Sciences? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Achieve Life Sciences. When is Achieve Life Sciences' next earnings date? Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Achieve Life Sciences. How were Achieve Life Sciences' earnings last quarter? Achieve Life Sciences Inc (NASDAQ:ACHV) posted its quarterly earnings results on Thursday, August, 6th. The biopharmaceutical company reported ($1.68) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($3.80) by $2.12. View Achieve Life Sciences' earnings history. When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work? Achieve Life Sciences shares reverse split before market open on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 5 shares after the split. What price target have analysts set for ACHV? 4 brokerages have issued 1 year price objectives for Achieve Life Sciences' shares. Their forecasts range from $21.00 to $100.00. On average, they expect Achieve Life Sciences' stock price to reach $47.75 in the next year. This suggests a possible upside of 406.4% from the stock's current price. View analysts' price targets for Achieve Life Sciences. Are investors shorting Achieve Life Sciences? Achieve Life Sciences saw a increase in short interest during the month of August. As of August 31st, there was short interest totaling 505,500 shares, an increase of 25.8% from the August 15th total of 401,800 shares. Based on an average daily volume of 524,900 shares, the short-interest ratio is currently 1.0 days. Currently, 22.1% of the shares of the stock are sold short. View Achieve Life Sciences' Short Interest. Who are some of Achieve Life Sciences' key competitors? Some companies that are related to Achieve Life Sciences include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), Immunomedics (IMMU), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX) and Exelixis (EXEL). View all competitors. What other stocks do shareholders of Achieve Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Novan (NOVN), AEterna Zentaris (AEZS), BioNano Genomics (BNGO), Zosano Pharma (ZSAN), Cannabics Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania R.E.I.T. (PEI). Who are Achieve Life Sciences' key executives? Achieve Life Sciences' management team includes the following people: Dr. Richard A. B. Stewart, Chairman & CEO (Age 60)Dr. Anthony Clarke, Pres, Chief Scientific Officer & Director (Age 63)Mr. John A. Bencich, Exec. VP, CFO & COO (Age 42)Dr. Cindy Jacobs, Exec. VP & Chief Medical Officer (Age 61)Ms. Jaime Xinos, Exec. VP of Commercial What is Achieve Life Sciences' stock symbol? Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV." Who are Achieve Life Sciences' major shareholders? Achieve Life Sciences' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Ikarian Capital LLC (233.33%), Requisite Capital Management LLC (63.78%) and UBS Group AG (0.29%). Company insiders that own Achieve Life Sciences stock include Armistice Capital Master Fund and Richard Alistair Stewart. View institutional ownership trends for Achieve Life Sciences. Which major investors are buying Achieve Life Sciences stock? ACHV stock was acquired by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Requisite Capital Management LLC, and UBS Group AG. Company insiders that have bought Achieve Life Sciences stock in the last two years include Armistice Capital Master Fund, and Richard Alistair Stewart. View insider buying and selling activity for Achieve Life Sciences. How do I buy shares of Achieve Life Sciences? Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Achieve Life Sciences' stock price today? One share of ACHV stock can currently be purchased for approximately $9.43. How big of a company is Achieve Life Sciences? Achieve Life Sciences has a market capitalization of $33.83 million. The biopharmaceutical company earns $-16,400,000.00 in net income (profit) each year or ($39.80) on an earnings per share basis. Achieve Life Sciences employs 13 workers across the globe. What is Achieve Life Sciences' official website? The official website for Achieve Life Sciences is achievelifesciences.com. How can I contact Achieve Life Sciences? Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
